Development Drug Trials Life Science 
XTalks
AUGUST 3, 2022
Hear more about raising awareness about rare diseases like vitiligo and how it can help foster the development of new treatments. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Read the full articles here: Zonisamide Liquid Form Gets FDA Approved for Epilepsy Treatment.
Velocity Clinical Research
OCTOBER 21, 2024
The clinical trials sector in the US is typically made up of small independent businesses that collectively play an important role in trialing new protocols and aiding drug development. This is vital if we’re to ensure that drug trials are inclusive and deliver results that are representative of the entire population.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 1, 2022
To ease this burden, the life sciences industry has been searching for ways to make clinical trials more accessible for patients and to drive participation numbers, increase participant diversity, and improve overall patient experience. Build a base in the community. Keep it simple. In fact, the opposite is true.
XTalks
APRIL 26, 2021
After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease. Malaria Vaccine Phase II Trial.
XTalks
MAY 16, 2023
The exact cause of pulmonary fibrosis is often unknown, and in such cases, it is referred to as idiopathic pulmonary fibrosis (IPF); however, certain factors can contribute to the development of pulmonary fibrosis, including environmental and occupational exposures, certain medications, autoimmune diseases and genetic predisposition.
Advarra
AUGUST 16, 2022
Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinical trial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. FDA Expedited Programs.
XTalks
SEPTEMBER 11, 2020
Clinical trials, however, don’t reflect that diversity. A study published in JAMA Oncology found that in cancer drug trials conducted between 2008 and 2018, nearly two-thirds of participants were non-Hispanic whites. When trial populations don’t match the broader patient base, the treatments they produce aren’t as effective.
Expert insights. Personalized for you.
52 
Let's personalize your content